Journalartikel

Jahr der Veröffentlichung: 2009

Seiten: 59-66

Zeitschrift: Aktuelle Rheumatologie

Bandnummer: 34

Heftnummer: 1

ISSN: 0341-051X

eISSN: 1438-9940

DOI Link: https://doi.org/10.1055/s-0028-1119370

Verlag: Georg Thieme Verlag

Abstract: 

Background: Methotrexate (MTX) is one of the most frequently used disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatic diseases. In clinical practice as well as in clinical trials, MTX is the gold standard for the treatment of rheumatoid arthritis. Nevertheless, a survey by the international 3E-initiative (Evidence, Experts, Exchange) among national and international experts identified 10 questions regarding the clinical use of MTX that had not yet been clarified. Therefore, it was the goal of this project to develop evidence-based recommendations on the use of MTX.

Materials and Methods: Between January and April 2007, experts from 17 countries agreed on 10 questions regarding the use of MTX. For answering these questions, "multinational fellows" performed a systematic literature research (SLR) up to October 2007. The SLR was completed according to the current recommendations of the Cochrane Collaboration and its results were presented to national groups of experts. Out of 17 000 articles retrieved by the SLR, only 304 articles were found to be applicable for answering the 10 questions. Based on these articles, recommendations were developed using a Delphi procedure.

Results: The 10 questions were divided into three topics: (A) therapeutic strategies, (B) treatment safety - monitoring and prevention and (C) treatment safety - complications. At the national meetings guided by the scientific committee, 68 German rheumatologists developed 10 recommendations in an interactive setting with a mean degree of acceptance of 90%.

Conclusion: The 3E-initiative has demonstrated that, despite long-standing experience with MTX, several issues with regard to its use in rheumatic diseases are currently unclear. The evidence-based recommendations on the use and monitoring of MTX as well as the management of therapeutic complications reported in this article represent the national consensus of experienced experts in the field and are of high importance for daily practice in rheumatology and for the development of future therapeutic recommendations.

Harvard-Zitierstil: Tarner, I., Manger, B., Fleck, M., Gromnica-Ihle, E., Keysser, G., Koehler, L., et al. (2009) Evidence-Based Recommendations of a National Group of Experts on the Use of Methotrexate in Inflammatory Rheumatic Diseases, Aktuelle Rheumatologie, 34(1), pp. 59-66. https://doi.org/10.1055/s-0028-1119370

APA-Zitierstil: Tarner, I., Manger, B., Fleck, M., Gromnica-Ihle, E., Keysser, G., Koehler, L., Koeetter, I., Krueger, K., Kuipers, J., Lorenz, H., Nuesslein, H., Rau, R., Rubbert, A., Schroeder, J., Wollenhaupt, J., & Mueller-Ladner, U. (2009). Evidence-Based Recommendations of a National Group of Experts on the Use of Methotrexate in Inflammatory Rheumatic Diseases. Aktuelle Rheumatologie. 34(1), 59-66. https://doi.org/10.1055/s-0028-1119370